Fig. 3: Pharmacodynamic and target engagement in the periphery for adjuvant treatment of melanoma. | Nature Medicine

Fig. 3: Pharmacodynamic and target engagement in the periphery for adjuvant treatment of melanoma.

From: Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial

Fig. 3

a, Expression of serum cytokines. b, Expression of surface LAG-3+ CD4 and CD8 T cells. c, Soluble LAG-3. a, Linear mixed-effect models per cytokine. Comparisons were between baseline and each on-treatment mean and of the mean of each arm for each timepoint. b, Linear mixed-effect models per flow populations. Comparisons of mean of each arm for each timepoint. c, Linear mixed-effect models for free soluble LAG-3. Comparisons were between baseline and each on-treatment mean and of the mean of each arm for each timepoint. Tests were two-sided t-tests for pairwise comparisons of estimated marginal means with 95% confidence interval (CI). No adjustment was made for multiple comparisons because each biomarker/timepoint was analyzed one at a time. NA, not applicable; NIVO, nivolumab; RELA relatlimab; wks, weeks.

Back to article page